HomePatientsLung Disease Week at the ATS2019 ▶ Sarcoidosis
Sarcoidosis Week


Welcome to Sarcoidosis Week at ATS! Sarcoidosis is an inflammatory disease with a largely unknown etiology. While the disease can affect any organ system, it commonly presents in the lung. Sarcoidosis is characterized by inflammatory granulomas that can affect the lung parenchyma and present in diverse phenotypes from small nodules to conglomerated masses to progressive fibrotic disease. Symptoms that patients with pulmonary sarcoidosis experience can include shortness of breath, cough, and chest pain as well as systemic symptoms including fever and fatigue. These symptoms are not exclusive for sarcoidosis and the diagnosis of the disease remains a diagnosis of exclusion. Several risk factors have been associated with sarcoidosis, such as race, genetic susceptibility, as well as geography and interaction of these risk factors plays an important role in disease pathogenesis. Currently, no curative treatment is available, however, immune-suppressive therapy is successfully used to manage the disease. The diversity of sarcoidosis clinical phenotypes, along with a complex interplay of risk factors make sarcoidosis diagnosis, treatment and management challenging. The ATS and the Foundation for Sarcoidosis Research is heavily invested in research to further understand the pathogenesis of distinct phenotypes of sarcoidosis with the goal to develop precision medicine approaches for better treatment and management of sarcoidosis patients. While the ATS and the Foundation for Sarcoidosis Research are devoted to support research that aim to improve quality of life and functionality of sarcoidosis patients, the ultimate goal is to cure the disease. To this end, significant progress has been made in basic and translational research that revealed that specific lymphocytes are critical for pathogenicity and chronicity of sarcoidosis, and more recently, potential autoimmune features of sarcoidosis have been discussed. These promising research findings represent the basis for the ATS and the Foundation for Sarcoidosis Research to focus and commit to further scientific discovery and thus moving closer to the overall goal to provide better care and potentially cure for patients suffering from this complex disease.



Melanie Königshoff MD, PhD
Professor of Medicine
Head, Fibrosis and Regeneration Program
Division of Pulmonary Sciences and Critical Care Medicine
Department of Medicine
University of Colorado


Tanzira Zaman, MD
Fellow in Pulmonary & Critical Care Medicine 
University of Colorado

Ginger Spitzer

Ginger Spitzer
Executive Director
Foundation for Sarcoidosis Research
Member, ATS Public Advisory Roundtable


ATS Sarcoidosis Partner
Foundation for Sarcoidosis Research



The Foundation for Sarcoidosis Research (FSR) is the nation's leading nonprofit organization dedicated to finding a cure for this disease and to improving care for sarcoidosis patients. Since its establishment in 2000, FSR has funded numerous domestic and international research efforts and has worked diligently to provide resources to thousands. FSR provides funding and collaborations for research and initiatives which focus on the understanding of sarcoidosis, addresses the causes of the disease, counters the suffering of patients, and advances the potential for a cure.